title: Bile-pancreatic juice replacement not cholinergic- and cholecystokinin-receptor blockade reverses acinar cell hyperstimulation after bile-pancreatic duct ligation.
abstract: BACKGROUND
  Acinar cell inhibitors (eg, atropine) fail to ameliorate clinical and experimental acute pancreatitis. We hypothesized that amelioration of pancreatic acinar cell hyperstimulation after bile and pancreatic duct ligation is better with gut replacement of bile and pancreatic juice than with cholinergic- and cholecystokinin (CCK)-receptor blockade.
  
  
  METHODS
  Using acinar cell amylase activity as an index of hyperstimulation, we studied 63 rats in two sets of experiments. Bile-pancreatic juice exclusion from gut--without (set one) and with (set two) bile and pancreatic duct obstruction--was treated with atropine and CCK-receptor antagonist L-364,718, or with enteral replacement of bile-pancreatic juice.
  
  
  RESULTS
  In the set one experiment, acinar cell hyperstimulation after bile-pancreatic juice exclusion was reversed by combined L-364,718 and atropine pretreatment. In set two, acinar cell hyperstimulation after bile and pancreatic duct ligation was reversed by enteral bile and pancreatic juice replacement, but not by combined L-364,718 and atropine pretreatment.
  
  
  CONCLUSIONS
  According to this experimental corollary of early gallstone impaction, prevention of acinar cell hyperstimulation after duct occlusion should be aimed at the source of the response to bile-pancreatic juice exclusion, namely, the gut, rather than at the target of the response, the pancreatic acinar cell.
authors.affiliation: Department of Surgery, Northwestern University Medical School, Chicago, Illinois 60611-2950, USA.
authors.forename: I
authors.initials: I
authors.lastname: Samuel
authors.forename: R J
authors.initials: RJ
authors.lastname: Joehl
mesh_terms: D000681:Amylases / Q000032:analysis; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001570:Benzodiazepinones / Q000494:pharmacology; D001646:Bile / Q000502:physiology*; D001652:Bile Ducts / Q000601:surgery; D018680:Cholinergic Antagonists; D020109:Devazepide; D008026:Ligation; D010179:Pancreas / Q000187:drug effects / Q000502:physiology*; D010183:Pancreatic Ducts / Q000601:surgery; D010189:Pancreatic Juice / Q000502:physiology*; D010195:Pancreatitis / Q000628:therapy; D051381:Rats; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*
chemical_list: D001570:Benzodiazepinones; D018680:Cholinergic Antagonists; D011949:Receptors, Cholecystokinin; D001285:Atropine; D000681:Amylases; D020109:Devazepide